Login to Your Account

Clinic Roundup

Thursday, February 7, 2013
• Seattle Genetics Inc., of Bothell, Wash, said it started two Phase I trials of SGN-CD19A, which uses the firm's antibody-drug conjugate technology. Both are open-label, dose-escalation trials, one in B-cell acute lymphoblastic leukemia and the other in B-cell non-Hodgkin's lymphomas, and both are designed to assess the safety and antitumor activity of the CD19-targeted drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription